#National Institutes of Health

However, there is hope that two HIV vaccines under investigation may at least cut transmission risk in half and qualify for mass use.

Today, with better understanding of the complex task at hand, cure researchers are investigating multiple avenues and taking the long view.

The iconic AIDS activist sounded off in a STAT interview—and shared how he’s spending his declining years.

U.S. activists unveil a national action plan to #BreakThePatent. It points out that taxpayers funded the research behind Truvada as PrEP.

NIH researchers have prompted animals to develop broadly neutralizing antibodies against the virus; an early human trial is in the works.

Promising news on the prevention front

The All of Us Research Program aims to collect data from 1 million people.

It’s the NIH’s first large-scale clinical trial on the subject. Plus: Meet organ transplant advocate Mo Murray [VIDEO].

Aside from taking antiretrovirals, quitting smoking is the number one way people with HIV can lower their risk of illness and death.

Researchers will genetically engineer participants’ CD4 cells, disabling the attachment of the virus.

At stake in amfAR’s civil war is the nonprofit’s quest to find a cure for HIV.

The CDC would keep fewer than 40 percent on employers on the job—and this is during a deadly flu outbreak.

This NIH study closely monitored 10 people with HIV who stopped antiretroviral treatment for weeks to months in a larger cure study.

A $3.4 million grant funds research about the HIV prevention pill in Milwaukee and Cleveland.

A one-month version of the ring is currently up for regulatory approval.

Courting controversy, the NIH considers a shift away from the development of new vaginal or rectal-based HIV prevention products.